MONDAY, Jan. 3, 2022 (HealthDay Knowledge) — For hospitalized COVID-19 patients, the presence of metabolic syndrome is expounded to increased odds of acute respiratory misery syndrome (ARDS) and mortality, primarily based on a uncover about published online Dec. 22 in JAMA Community Start.
Joshua L. Denson, M.D., from the Tulane College School of Pills in New Orleans, and colleagues conducted a multicenter cohort uncover about to see whether or no longer metabolic syndrome is expounded to an increased risk for ARDS and loss of life from COVID-19. Outcomes believe been in contrast for patients hospitalized with COVID-19 with metabolic syndrome (three or more of the following: weight problems, prediabetes or diabetes, hypertension, dyslipidemia; 5,069 adults) and controls with out metabolic syndrome (23,971 adults).
The researchers chanced on that metabolic syndrome used to be connected to an increased risk for intensive care unit (ICU) admission, invasive mechanical ventilation, ARDS, and mortality (adjusted odds ratios, 1.32, 1.45, 1.36, and 1.19, respectively) and with prolonged health center and ICU dimension of contend with (median, 8.0 versus 6.8 days and 7.0 versus 6.4 days, respectively). The risk for ARDS increased in an additive plot with every additional metabolic syndrome criterion (one criterion: 10.4 percent; two standards: 15.3 percent; three standards: 19.3 percent; four standards: 24.3 percent).
“Given the high rates of metabolic syndrome, weight problems, and diabetes in america, one hypothesis for why america led the sphere in COVID-19 circumstances and deaths could perchance perchance properly be the high prevalence of metabolic syndrome in this population,” the authors write.
Several authors disclosed monetary ties to the pharmaceutical industry.
